{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:07:22Z","timestamp":1788862042696,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>The management of end-stage heart failure in cardiac amyloidosis due to both light chain (AL-CA) and transthyretin (ATTR-CA) with heart transplantation has historically been limited by concerns about systemic progression after transplant. As a result, heart transplantation as a strategy was often restrictive and many patients were excluded. This review synthesizes contemporary evidence and outlines a practical framework to guide heart transplant evaluation and decision making in advanced disease. We emphasize evolving multidisciplinary selection principles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>In the recent era (since the 2010s), multicenter experience has demonstrated that carefully selected patients with advanced AL-CA and ATTR-CA can achieve favorable outcomes after heart transplantation. Specifically, selected individuals with wild type transthyretin cardiac amyloidosis (ATTRwt-CA) may be appropriate candidates. For hereditary transthyretin cardiac amyloidosis (ATTRv-CA), isolated heart or combined heart liver transplantation (CHLT) can been considered, although modern transthyretin targeted therapies increasingly influence this decision. Patients with AL-CA may undergo transplantation alongside timely plasma cell directed treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Historically, outcomes for heart transplantation in patients with cardiac amyloidosis were poor. Improved patient selection as well as advances in plasma cell targeted therapy for AL-CA and transthyretin stabilizing or gene silencing treatments for ATTR-CA have reshaped expectations. The improved outcomes seen in more contemporary cohorts support heart transplantation as a viable option for selected patients with advanced disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11897-026-00777-6","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:07:19Z","timestamp":1788858439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Amyloidosis &amp; Advanced Heart Failure: When to Consider Cardiac Transplantation and What are the Results?"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-4322","authenticated-orcid":false,"given":"Steven","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Patolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"16","key":"777_CR1","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072.","journal-title":"Eur Heart J"},{"issue":"11","key":"777_CR2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"13","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med Sep. 2018;13(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med Sep"},{"issue":"2","key":"777_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2305434.","journal-title":"N Engl J Med"},{"issue":"1","key":"777_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","journal-title":"N Engl J Med"},{"issue":"1","key":"777_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021;385(1):46\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2028631.","journal-title":"N Engl J Med"},{"issue":"10","key":"777_CR6","doi-asserted-by":"publisher","first-page":"e14028","DOI":"10.1111\/ctr.14028","volume":"34","author":"JM Griffin","year":"2020","unstructured":"Griffin JM, Chiu L, Axsom KM, et al. United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clin Transpl Oct. 2020;34(10):e14028. https:\/\/doi.org\/10.1111\/ctr.14028.","journal-title":"Clin Transpl Oct"},{"key":"777_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1075806","author":"Y Razvi","year":"2023","unstructured":"Razvi Y, Porcari A, Di Nora C, et al. Cardiac transplantation in transthyretin amyloid cardiomyopathy: outcomes from three decades of tertiary center experience. Front Cardiovasc Med. 2023. https:\/\/doi.org\/10.3389\/fcvm.2022.1075806.","journal-title":"Front Cardiovasc Med"},{"issue":"30","key":"777_CR8","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2017","unstructured":"Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2017;39(30):2799\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589.","journal-title":"Eur Heart J"},{"issue":"11","key":"777_CR9","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1097\/tp.0000000000002240","volume":"102","author":"AN Rosenbaum","year":"2018","unstructured":"Rosenbaum AN, AbouEzzeddine OF, Grogan M, et al. Outcomes after cardiac transplant for wild type transthyretin amyloidosis. Transplantation. 2018;102(11):1909\u201313. https:\/\/doi.org\/10.1097\/tp.0000000000002240.","journal-title":"Transplantation"},{"issue":"2","key":"777_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.healun.2021.10.007","volume":"41","author":"JM Griffin","year":"2022","unstructured":"Griffin JM, Baughan E, Rosenblum H, et al. Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. J Heart Lung Transplant. 2022;41(2):199\u2013207. https:\/\/doi.org\/10.1016\/j.healun.2021.10.007.","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"777_CR11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.healun.2024.05.010","volume":"43","author":"Y Peled","year":"2024","unstructured":"Peled Y, Ducharme A, Kittleson M, et al. International Society for Heart and Lung Transplantation guidelines for the evaluation and care of cardiac transplant candidates\u20142024. J Heart Lung Transplant. 2024;43(10):1529-1628.e54. https:\/\/doi.org\/10.1016\/j.healun.2024.05.010.","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"777_CR12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.healun.2024.05.010","volume":"43","author":"Y Peled","year":"2024","unstructured":"Peled Y, Ducharme A, Kittleson M, et al. International Society for Heart and Lung Transplantation guidelines for the evaluation and care of cardiac transplant candidates-2024. J Heart Lung Transplant. 2024;43(10):1529-1628.e54. https:\/\/doi.org\/10.1016\/j.healun.2024.05.010.","journal-title":"J Heart Lung Transplant"},{"key":"777_CR13","doi-asserted-by":"publisher","unstructured":"Punnoose LR, Siddiqi H, Rosenthal JL, Kittleson M, Witteles R, Alexander K. Implications of extra-cardiac disease in patient selection for heart transplantation: considerations in cardiac amyloidosis. Cardiac Failure Review. 2023;9:e01. https:\/\/doi.org\/10.15420\/cfr.2022.24","DOI":"10.15420\/cfr.2022.24"},{"issue":"11","key":"777_CR14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"21","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol Mar. 2023;21(11):1076\u2013126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022.","journal-title":"J Am Coll Cardiol Mar"},{"issue":"6","key":"777_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cld.812","volume":"13","author":"K Zhao","year":"2019","unstructured":"Zhao K, McLean RC, Hoteit MA, Olthoff KM. Combined heart and liver transplant: indication, patient selection, and allocation policy. Clin Liver Dis (Hoboken). 2019;13(6):170\u20135. https:\/\/doi.org\/10.1002\/cld.812.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"23","key":"777_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2025.104646","volume":"30","author":"RK Neicheril","year":"2025","unstructured":"Neicheril RK, Chacon D, Snipelisky D. Successful heart and kidney transplant in end-stage wild-type TTR amyloidosis and renal failure. JACC Case Rep. 2025;30(23):104646. https:\/\/doi.org\/10.1016\/j.jaccas.2025.104646.","journal-title":"JACC Case Rep"},{"issue":"8","key":"777_CR17","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1016\/j.cardfail.2019.07.484","volume":"25","author":"DR Fermin","year":"2019","unstructured":"Fermin DR, Cohle SD, Twydell PT, Dickinson MG. Early Recurrence of Myocardial Transthyretin Amyloid Deposition Three Years Post Heart Transplantation for Hereditary V40I Amyloidosis. J Card Fail. 2019;25(8):S170. https:\/\/doi.org\/10.1016\/j.cardfail.2019.07.484.","journal-title":"J Card Fail"},{"issue":"5","key":"777_CR18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.healun.2014.09.006","volume":"34","author":"MK Davis","year":"2015","unstructured":"Davis MK, Lee PHU, Witteles RM. Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2015;34(5):658\u201366. https:\/\/doi.org\/10.1016\/j.healun.2014.09.006.","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"777_CR19","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.mayocp.2025.05.009","volume":"100","author":"MA Lyle","year":"2025","unstructured":"Lyle MA, Rosenthal JL, Nativi Nicolau JN, et al. Heart transplantation for cardiac amyloidosis: Mayo Clinic consensus statement. Mayo Clin Proc. 2025;100(9):1578\u2013605. https:\/\/doi.org\/10.1016\/j.mayocp.2025.05.009.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"777_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/TP.0000000000001021","volume":"100","author":"OB Suhr","year":"2016","unstructured":"Suhr OB, Larsson M, Ericzon BG, Wilczek HE, investigators FAs. Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry. Transplantation Feb. 2016;100(2):373\u201381. https:\/\/doi.org\/10.1097\/TP.0000000000001021.","journal-title":"Transplantation Feb"},{"issue":"2","key":"777_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3109\/13506129.2013.853660","volume":"21","author":"T Thenappan","year":"2014","unstructured":"Thenappan T, Fedson S, Rich J, et al. Isolated heart transplantation for familial transthyretin (TTR) V122I cardiac amyloidosis. Amyloid. 2014;21(2):120\u20133. https:\/\/doi.org\/10.3109\/13506129.2013.853660.","journal-title":"Amyloid"},{"issue":"5","key":"777_CR22","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.1600-6143.2008.02162.x","volume":"8","author":"IM Hamour","year":"2008","unstructured":"Hamour IM, Lachmann HJ, Goodman HJ, et al. Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant. 2008;8(5):1056\u20139. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02162.x.","journal-title":"Am J Transplant"},{"issue":"7","key":"777_CR23","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/00007890-199804150-00010","volume":"15","author":"EA Pomfret","year":"1998","unstructured":"Pomfret EA, Lewis WD, Jenkins RL, et al. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation Apr. 1998;15(7):918\u201325. https:\/\/doi.org\/10.1097\/00007890-199804150-00010.","journal-title":"Transplantation Apr"},{"issue":"24","key":"777_CR24","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra2304088","volume":"390","author":"V Sanchorawala","year":"2024","unstructured":"Sanchorawala V. Systemic light chain amyloidosis. N Engl J Med. 2024;390(24):2295\u2013307. https:\/\/doi.org\/10.1056\/NEJMra2304088.","journal-title":"N Engl J Med"},{"issue":"4","key":"777_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaccao.2022.08.009","volume":"4","author":"AD Wechalekar","year":"2022","unstructured":"Wechalekar AD, Fontana M, Quarta CC, Liedtke M. AL amyloidosis for cardiologists. JACC CardioOncology. 2022;4(4):427\u201341. https:\/\/doi.org\/10.1016\/j.jaccao.2022.08.009.","journal-title":"JACC CardioOncology"},{"issue":"9","key":"777_CR26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/jco.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395. https:\/\/doi.org\/10.1200\/jco.2011.38.5724.","journal-title":"J Clin Oncol"},{"key":"777_CR27","doi-asserted-by":"publisher","unstructured":"Kumar SK, Gertz MA, Lacy MQ et al. Jan. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12-8. https:\/\/doi.org\/10.4065\/mcp.2010.0480","DOI":"10.4065\/mcp.2010.0480"},{"key":"777_CR28","doi-asserted-by":"publisher","unstructured":"Dispenzieri A, Gertz MA, Kyle RA et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 22(18):3751\u20137. https:\/\/doi.org\/10.1200\/JCO.2004.03.029","DOI":"10.1200\/JCO.2004.03.029"},{"issue":"3","key":"777_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","volume":"133","author":"B Lilleness","year":"2019","unstructured":"Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood. 2019;133(3):215\u201323. https:\/\/doi.org\/10.1182\/blood-2018-06-858951.","journal-title":"Blood"},{"key":"777_CR30","doi-asserted-by":"publisher","unstructured":"Kittleson Michelle M, Ruberg Frederick L, Ambardekar Amrut V et al. 2023 ACC Expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. JACC. 2023;81(11):1076\u2013126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022","DOI":"10.1016\/j.jacc.2022.11.022"},{"issue":"5","key":"777_CR31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.healun.2017.02.010","volume":"36","author":"J Baumwol","year":"2017","unstructured":"Baumwol J. \u201cI need help\u201d\u2014a mnemonic to aid timely referral in advanced heart failure. J Heart Lung Transplant. 2017;36(5):593\u20134. https:\/\/doi.org\/10.1016\/j.healun.2017.02.010.","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"777_CR32","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","volume":"32","author":"E Muchtar","year":"2018","unstructured":"Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018;32(10):2240\u20139. https:\/\/doi.org\/10.1038\/s41375-018-0060-x.","journal-title":"Leukemia"},{"issue":"10","key":"777_CR33","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/eurjhf\/hfp121","volume":"11","author":"AV Kristen","year":"2009","unstructured":"Kristen AV, Sack F-U, Schonland SO, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail. 2009;11(10):1014\u201320. https:\/\/doi.org\/10.1093\/eurjhf\/hfp121.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"777_CR34","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1111\/ajt.15487","volume":"19","author":"BH Trachtenberg","year":"2019","unstructured":"Trachtenberg BH, Kamble RT, Rice L, et al. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. Am J Transplant. 2019;19(10):2900\u20139. https:\/\/doi.org\/10.1111\/ajt.15487.","journal-title":"Am J Transplant"},{"issue":"2","key":"777_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ajt.16324","volume":"21","author":"DP Al-Adra","year":"2021","unstructured":"Al-Adra DP, Hammel L, Roberts J, et al. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transpl Feb. 2021;21(2):475\u201383. https:\/\/doi.org\/10.1111\/ajt.16324.","journal-title":"Am J Transpl Feb"},{"issue":"6","key":"777_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14308","volume":"35","author":"GN Vaidya","year":"2021","unstructured":"Vaidya GN, Patel JK, Kittleson M, et al. Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era. Clin Transplant. 2021;35(6):e14308. https:\/\/doi.org\/10.1111\/ctr.14308.","journal-title":"Clin Transplant"},{"issue":"6","key":"777_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jchf.2019.12.013","volume":"8","author":"CD Barrett","year":"2020","unstructured":"Barrett CD, Alexander KM, Zhao H, et al. Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC Heart Fail Jun. 2020;8(6):461\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2019.12.013.","journal-title":"JACC Heart Fail Jun"},{"issue":"6","key":"777_CR38","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.hoc.2020.09.001","volume":"34","author":"M Rosenzweig","year":"2020","unstructured":"Rosenzweig M, Comenzo RL. Liver and gastrointestinal involvement. Hematol Oncol Clin North Am. 2020;34(6):1081\u201390. https:\/\/doi.org\/10.1016\/j.hoc.2020.09.001.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"777_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79(4):319\u201328. https:\/\/doi.org\/10.1002\/ajh.20381.","journal-title":"Am J Hematol"},{"issue":"5","key":"777_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/01.md.0000091183.93122.c7","volume":"82","author":"MA Park","year":"2003","unstructured":"Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Med (Baltimore) Sep. 2003;82(5):291\u20138. https:\/\/doi.org\/10.1097\/01.md.0000091183.93122.c7.","journal-title":"Med (Baltimore) Sep"},{"issue":"5","key":"777_CR41","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","volume":"78","author":"LA Inker","year":"2021","unstructured":"Inker LA, Titan S. Measurement and estimation of GFR for use in clinical practice: core curriculum 2021. Am J Kidney Dis. 2021;78(5):736\u201349. https:\/\/doi.org\/10.1053\/j.ajkd.2021.04.016.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"777_CR42","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1148\/rg.2015140179","volume":"35","author":"F Czeyda-Pommersheim","year":"2015","unstructured":"Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman C, Bhalla S. Amyloidosis: modern cross-sectional imaging. Radiographics. 2015;35(5):1381\u201392. https:\/\/doi.org\/10.1148\/rg.2015140179.","journal-title":"Radiographics"},{"issue":"10","key":"777_CR43","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.healun.2003.08.027","volume":"23","author":"SW Dubrey","year":"2004","unstructured":"Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23(10):1142\u201353. https:\/\/doi.org\/10.1016\/j.healun.2003.08.027.","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"777_CR44","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.healun.2008.05.016","volume":"27","author":"MQ Lacy","year":"2008","unstructured":"Lacy MQ, Dispenzieri A, Hayman SR, et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transpl Aug. 2008;27(8):823\u20139. https:\/\/doi.org\/10.1016\/j.healun.2008.05.016.","journal-title":"J Heart Lung Transpl Aug"},{"issue":"5","key":"777_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.healun.2017.11.015","volume":"37","author":"AV Kristen","year":"2018","unstructured":"Kristen AV, Kreusser MM, Blum P, et al. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era. J Heart Lung Transpl May. 2018;37(5):611\u20138. https:\/\/doi.org\/10.1016\/j.healun.2017.11.015.","journal-title":"J Heart Lung Transpl May"},{"key":"777_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhlto.2025.100328","author":"K Patel","year":"2025","unstructured":"Patel K, Tu ZH, Yuen C, et al. Long-term outcomes of light chain amyloidosis patients receiving heart transplant: A single-center experience. JHLT Open. 2025. https:\/\/doi.org\/10.1016\/j.jhlto.2025.100328. \/08\/01\/ 2025;9:100328.","journal-title":"JHLT Open"},{"issue":"3","key":"777_CR47","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.healun.2011.09.010","volume":"31","author":"BC Varr","year":"2012","unstructured":"Varr BC, Liedtke M, Arai S, Lafayette RA, Schrier SL, Witteles RM. Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies. J Heart Lung Transplant. 2012;31(3):325\u201331. https:\/\/doi.org\/10.1016\/j.healun.2011.09.010.","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"777_CR48","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.transproceed.2020.08.020","volume":"53","author":"Q Chen","year":"2021","unstructured":"Chen Q, Moriguchi J, Levine R, et al. Outcomes of heart transplantation in cardiac amyloidosis patients: a single center experience. Transplant Proc. 2021;53(1):329\u201334. https:\/\/doi.org\/10.1016\/j.transproceed.2020.08.020.","journal-title":"Transplant Proc"},{"issue":"2","key":"777_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.healun.2013.09.004","volume":"33","author":"L Gray Gilstrap","year":"2014","unstructured":"Gray Gilstrap L, Niehaus E, Malhotra R, et al. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant. 2014;33(2):149\u201356. https:\/\/doi.org\/10.1016\/j.healun.2013.09.004.","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"777_CR50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.14797\/mdcj-8-3-8","volume":"8","author":"JD Estep","year":"2012","unstructured":"Estep JD, Bhimaraj A, Cordero-Reyes AM, Bruckner B, Loebe M, Torre-Amione G. Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management. Methodist Debakey Cardiovasc J. 2012;8(3):8\u201316. https:\/\/doi.org\/10.14797\/mdcj-8-3-8.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"21","key":"777_CR51","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood.2019003807","volume":"135","author":"V Royal","year":"2020","unstructured":"Royal V, Leung N, Troyanov S, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood. 2020;135(21):1833\u201346. https:\/\/doi.org\/10.1182\/blood.2019003807.","journal-title":"Blood"},{"issue":"7","key":"777_CR52","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/TP.0b013e3181cd4abb","volume":"89","author":"B Labban","year":"2010","unstructured":"Labban B, Arora N, Restaino S, Markowitz G, Valeri A, Radhakrishnan J. The role of kidney biopsy in heart transplant candidates with kidney disease. Transplantation. 2010;89(7):887\u201393. https:\/\/doi.org\/10.1097\/TP.0b013e3181cd4abb.","journal-title":"Transplantation"},{"issue":"4","key":"777_CR53","doi-asserted-by":"publisher","first-page":"S531","DOI":"10.1016\/j.healun.2024.02.763","volume":"43","author":"S Perdikis","year":"2024","unstructured":"Perdikis S, Kao A, Barat M, et al. Orthotopic Heart and Multi-Organ Transplantation in AL Amyloidosis. J Heart Lung Transplantation. 2024;43(4):S531\u20132. https:\/\/doi.org\/10.1016\/j.healun.2024.02.763.","journal-title":"J Heart Lung Transplantation"},{"issue":"7","key":"777_CR54","doi-asserted-by":"publisher","DOI":"10.1097\/txd.0000000000001323","volume":"8","author":"S Guendouz","year":"2022","unstructured":"Guendouz S, Grimbert P, Radu C, et al. Heart transplantation, either alone or combined with liver and kidney, a viable treatment option for selected patients with severe cardiac amyloidosis. Transplant Direct. 2022;8(7):e1323. https:\/\/doi.org\/10.1097\/txd.0000000000001323.","journal-title":"Transplant Direct"},{"issue":"4","key":"777_CR55","doi-asserted-by":"publisher","first-page":"S557","DOI":"10.1016\/j.healun.2024.02.821","volume":"43","author":"A Birs","year":"2024","unstructured":"Birs A, Urey M, Adler E, et al. Heart and lung transplant in a patient with relapsed AL amyloidosis. J Heart Lung Transplant. 2024;43(4):S557\u20138. https:\/\/doi.org\/10.1016\/j.healun.2024.02.821.","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"777_CR56","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/ehf2.13422","volume":"8","author":"VK Randhawa","year":"2021","unstructured":"Randhawa VK, Gabrovsek A, Soltesz EG, et al. A case series of cardiac amyloidosis patients supported by continuous-flow left ventricular assist device. ESC Heart Fail. 2021;8(5):4353\u20136. https:\/\/doi.org\/10.1002\/ehf2.13422.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"777_CR57","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaccao.2021.05.007","volume":"3","author":"RM Witteles","year":"2021","unstructured":"Witteles RM. Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis. JACC CardioOncol Oct. 2021;3(4):516\u201321. https:\/\/doi.org\/10.1016\/j.jaccao.2021.05.007.","journal-title":"JACC CardioOncol Oct"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-026-00777-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:07:20Z","timestamp":1788858440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-026-00777-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s11897-026-00777-6","relation":{},"ISSN":["1546-9549"],"issn-type":[{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Steven Hamilton and Harsh Patolia certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. Mazen Hanna has served on advisory boards for Pfizer, Alnylam, Ionis, BridgeBio, Alexion, and Novo Nordisk.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"44"}}